<DOC>
	<DOCNO>NCT01266525</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate efficacy least one dose SAR110894 ( H3 receptor antagonist ) comparison placebo cognitive performance patient mild moderate Alzheimer 's disease ( AD ) stable donepezil therapy Secondary Objectives : - To explore effect SAR110894 functional impairment , global clinical status behavioral disturbance ; - To assess safety/tolerability SAR110894 ; - To assess pharmacokinetic ( PK ) SAR110894 concentration donepezil ; - To explore caregiver time consumption distress change .</brief_summary>
	<brief_title>Effect Different Doses SAR110894 Cognition Patients With Mild Moderate Alzheimer 's Disease Donepezil</brief_title>
	<detailed_description>The total study duration patient approximatively 36 - 38 week broken follow : - Screening period : 4 week , - Treatment period : 24 week , - Follow-up period : 10 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Patients diagnosis Alzheimer 's Disease ( AD ) ( Can dementia stroke cause ) . Patient stable welltolerated donepezil treatment dose either 5 10 mg daily least 3 month prior screen visit . Exclusion criterion : Age &lt; 55 year old . Psychotic feature , agitation , behavioral problem within last 3 month . Patients unable comply ophthalmologic monitoring . Lack consistent reliable caregiver . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>